-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
NoveCite has signed an exclusive license agreement with Novellus Therapeutics Limited to develop and commercialize the interstuming stem cells (NC-iMSCs) from NoveCite's induced omnicroid stem cells (iPSC) sources to treat acute respiratory distress, including acute respiratory distress syndrome (ARDS) caused by infection with the new coronavirus COVID-19.
early clinical trials using MSC to treat ARDS have shown that cell therapy can reduce inflammation, increase pathogen removal and stimulate lung tissue repair, according to Citius Pharmaceuticals, the parent company of NoveCite.
the company noted that iMSC is the next generation of MSC therapy, which is significantly different from MSC from the source of the supply, as the iMSC overcomes a variety of challenges associated with the supply source MSC, such as variable supply and tissue sources, limited availability, high cost and inefficiency.
According to Citius, iMSCs are more effective, secreting immunomodulation protein levels are increasing exponentially; supply is virtually unlimited; mass production of stable mass and potency can be made after cloning from a single supply; and amplification capacity is significantly improved.
3 million ARDS cases worldwide each year, of which about 200,000 occur in the United States.
the COVID-19 pandemic has greatly increased the number of ARDS cases.
when COVID-19 patients develop ARDS, the patient mortality rate is still as high as 50% on the basis of the use of a ventilator, and there is currently no approved treatment.
picture source:
